(Q53084014)

English

Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2†.

scientific article published on 17 September 2014

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

30 June 2019

http://europepmc.org/abstract/PMC/6267855

Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2†. (English)

1 reference

Europe PubMed Central

30 June 2019

http://europepmc.org/abstract/PMC/6267855

14

1 reference

Europe PubMed Central

11 May 2018

http://europepmc.org/abstract/MED/25231953

20

object named as

J Baselga

1 reference

Europe PubMed Central

11 May 2018

9

object named as

H S Rugo

1 reference

Europe PubMed Central

30 June 2019

http://europepmc.org/abstract/PMC/6267855

author name string

M Piccart

1

1 reference

Europe PubMed Central

30 June 2019

http://europepmc.org/abstract/PMC/6267855

G N Hortobagyi

2

1 reference

Europe PubMed Central

30 June 2019

http://europepmc.org/abstract/PMC/6267855

M Campone

3

1 reference

Europe PubMed Central

30 June 2019

http://europepmc.org/abstract/PMC/6267855

K I Pritchard

4

1 reference

Europe PubMed Central

30 June 2019

http://europepmc.org/abstract/PMC/6267855

F Lebrun

5

1 reference

Europe PubMed Central

30 June 2019

http://europepmc.org/abstract/PMC/6267855

Y Ito

6

1 reference

Europe PubMed Central

30 June 2019

http://europepmc.org/abstract/PMC/6267855

S Noguchi

7

1 reference

Europe PubMed Central

30 June 2019

http://europepmc.org/abstract/PMC/6267855

A Perez

8

1 reference

Europe PubMed Central

30 June 2019

http://europepmc.org/abstract/PMC/6267855

I Deleu

10

1 reference

Europe PubMed Central

30 June 2019

http://europepmc.org/abstract/PMC/6267855

H A Burris

11

1 reference

Europe PubMed Central

30 June 2019

http://europepmc.org/abstract/PMC/6267855

L Provencher

12

1 reference

Europe PubMed Central

30 June 2019

http://europepmc.org/abstract/PMC/6267855

P Neven

13

1 reference

Europe PubMed Central

30 June 2019

http://europepmc.org/abstract/PMC/6267855

M Shtivelband

15

1 reference

Europe PubMed Central

30 June 2019

http://europepmc.org/abstract/PMC/6267855

C Wu

16

1 reference

Europe PubMed Central

30 June 2019

http://europepmc.org/abstract/PMC/6267855

J Fan

17

1 reference

Europe PubMed Central

30 June 2019

http://europepmc.org/abstract/PMC/6267855

W Feng

18

1 reference

Europe PubMed Central

30 June 2019

http://europepmc.org/abstract/PMC/6267855

T Taran

19

1 reference

Europe PubMed Central

30 June 2019

http://europepmc.org/abstract/PMC/6267855

publication date

17 September 2014

1 reference

Europe PubMed Central

30 June 2019

http://europepmc.org/abstract/PMC/6267855

Annals of Oncology

1 reference

Europe PubMed Central

30 June 2019

http://europepmc.org/abstract/PMC/6267855

25

1 reference

Europe PubMed Central

30 June 2019

http://europepmc.org/abstract/PMC/6267855

2357-2362

1 reference

Europe PubMed Central

30 June 2019

http://europepmc.org/abstract/PMC/6267855

12

1 reference

Europe PubMed Central

30 June 2019

http://europepmc.org/abstract/PMC/6267855

Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group.

1 reference

https://pubmed.ncbi.nlm.nih.gov/25231953

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase

1 reference

https://pubmed.ncbi.nlm.nih.gov/25231953

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance

1 reference

https://pubmed.ncbi.nlm.nih.gov/25231953

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells.

1 reference

https://pubmed.ncbi.nlm.nih.gov/25231953

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/25231953

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism.

1 reference

https://pubmed.ncbi.nlm.nih.gov/25231953

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT.

1 reference

https://pubmed.ncbi.nlm.nih.gov/25231953

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/25231953

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Biological determinants of endocrine resistance in breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/25231953

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/25231953

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM

1 reference

https://pubmed.ncbi.nlm.nih.gov/25231953

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer.

1 reference

https://pubmed.ncbi.nlm.nih.gov/25231953

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Gefitinib or placebo in combination with tamoxifen in patients with hormone receptor-positive metastatic breast cancer: a randomized phase II study

1 reference

https://pubmed.ncbi.nlm.nih.gov/25231953

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Biological mechanisms and clinical implications of endocrine resistance in breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/25231953

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/25231953

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/25231953

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

1st International consensus guidelines for advanced breast cancer (ABC 1).

1 reference

https://pubmed.ncbi.nlm.nih.gov/25231953

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study

1 reference

https://pubmed.ncbi.nlm.nih.gov/25231953

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Combination anastrozole and fulvestrant in metastatic breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/25231953

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Mammalian target of rapamycin as a rational therapeutic target for breast cancer treatment

1 reference

https://pubmed.ncbi.nlm.nih.gov/25231953

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized phase III placebo-controlled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer.

1 reference

https://pubmed.ncbi.nlm.nih.gov/25231953

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Mechanisms of resistance to endocrine therapy in breast cancer: focus on signaling pathways, miRNAs and genetically based resistance.

1 reference

https://pubmed.ncbi.nlm.nih.gov/25231953

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Ganitumab with either exemestane or fulvestrant for postmenopausal women with advanced, hormone-receptor-positive breast cancer: a randomised, controlled, double-blind, phase 2 trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/25231953

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Health-related quality of life of patients with advanced breast cancer treated with everolimus plus exemestane versus placebo plus exemestane in the phase 3, randomized, controlled, BOLERO-2 trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/25231953

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a nonsteroidal a

1 reference

https://pubmed.ncbi.nlm.nih.gov/25231953

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/25231953

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

1 reference

https://pubmed.ncbi.nlm.nih.gov/25231953

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, mult

1 reference

https://pubmed.ncbi.nlm.nih.gov/25231953

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis

1 reference

https://pubmed.ncbi.nlm.nih.gov/25231953

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Activating ESR1 mutations in hormone-resistant metastatic breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/25231953

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

ESR1 ligand-binding domain mutations in hormone-resistant breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/25231953

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Final overall survival: fulvestrant 500 mg vs 250 mg in the randomized CONFIRM trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/25231953

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Emergence of constitutively active estrogen receptor-α mutations in pretreated advanced estrogen receptor-positive breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/25231953

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

ESR1 gene promoter region methylation in free circulating DNA and its correlation with estrogen receptor protein expression in tumor tissue in breast cancer patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/25231953

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study

1 reference

https://pubmed.ncbi.nlm.nih.gov/25231953

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2.

1 reference

https://pubmed.ncbi.nlm.nih.gov/25231953

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1093/ANNONC/MDU456

1 reference

Europe PubMed Central

30 June 2019

http://europepmc.org/abstract/PMC/6267855

1 reference

Europe PubMed Central

30 June 2019

http://europepmc.org/abstract/PMC/6267855

1 reference

Europe PubMed Central

30 June 2019

http://europepmc.org/abstract/PMC/6267855

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53084014&oldid=1854798443"